v3.26.1
Condensed Statements of Operations - USD ($)
 7 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2025
Archimedes Tech SPAC Partners II Co    
General and administrative expenses $ 78,700 $ 785,975
Loss from operations (78,700) (785,975)
Other income:    
Interest earned on cash in bank account   8,710,969
Total other income 0 8,772,713
Net income (loss) $ (78,700) [1] $ 7,986,738
Redeemable Ordinary Shares [Member] | Archimedes Tech SPAC Partners II Co    
Other income:    
Basic and diluted weighted average shares outstanding, redeemable ordinary shares (in shares) 0 20,290,411
Basic and diluted net income per share, redeemable ordinary shares (in dollars per share) $ 0 $ 0.3
Diluted weighted average shares outstanding, non-redeemable ordinary shares (in shares)   20,290,411
Diluted net income (loss) per share, non-redeemable ordinary shares (in dollars per share)   $ 0.3
Non-redeemable Ordinary Shares [Member] | Archimedes Tech SPAC Partners II Co    
Other income:    
Basic and diluted weighted average shares outstanding, redeemable ordinary shares (in shares) [2] 5,000,000 6,402,685
Basic and diluted net income per share, redeemable ordinary shares (in dollars per share) $ (0.02) $ 0.3
Diluted weighted average shares outstanding, non-redeemable ordinary shares (in shares) [2] 5,000,000 6,488,986
Diluted net income (loss) per share, non-redeemable ordinary shares (in dollars per share) $ (0.02) $ 0.3
Cash In Bank Account [Member] | Archimedes Tech SPAC Partners II Co    
Other income:    
Interest earned on cash in bank account $ 0 $ 61,744
Cash Held In Trust Account [Member] | Archimedes Tech SPAC Partners II Co    
Other income:    
Interest earned on cash in bank account $ 0 $ 8,710,969
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.
[2] Prior to the Company’s Initial Public Offering, the ordinary shares excluded an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.